drugset
drugset / Trial / NCT05326347

A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

NCT05326347 ↗

Phase 3 Completed 247 enrolled Otsuka Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia

Timeline

Start
2022-05-31
Primary completion
2025-08-26
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 48 mg Oral

Indications

schizophrenia